TOKYO -- Swiss pharmaceutical company Novartis has pegged its cancer-targeting radiopharmaceutical business as its next growth pillar, looking to make it "at least a $10 billion business" over the next decade, CEO Vasant Narasimhan told Nikkei in an interview.
Pharmaceuticals
Novartis sees radioactive cancer drugs becoming $10bn business: CEO
Company to also focus on areas it can innovate in over crowded anti-obesity market
Norvartis CEO Vasant Narasimhan said his company's market cap has grown more than $40 billion since 2018. (Photo by Hideki Yoshikawa)
Read Next
.JPG?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
Latest on Pharmaceuticals
